Skip to main content
OpenTrials
Completed

NCT Number: NCT01745211

755nm Alex Laser for Treatment of Stretch Marks

Evaluate the safety and efficacy of the bilateral treatment of striae using a 755nm Alexandrite laser.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Striae Pathological Conditions, Signs and Symptoms Signs and Symptoms Skin Manifestations Striae Distensae

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Laser & Skin Surgery Center of New York

New York, 10016, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is a healthy male or female between 18 and 85 years old.
  • Has unwanted striae and wishes to undergo laser treatments to remove or improve them.
  • Is willing to consent to participate in the study.
  • Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits.

Exclusion criteria

  • Is hypersensitive to light exposure.
  • Has active localized or systemic infection.
  • Is taking medication(s) for which sunlight is a contraindication.
  • Has a history of squamous cell carcinoma or melanoma.
  • Has a history of keloid scarring.
  • Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.
  • Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.
  • Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
  • Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine.
  • Has any other reason determined by the physician to be ineligible to participate in the study.

Treatment and study plan

755nm Alexandrite Laser

Device

755nm Alexandrite laser with array handpiece

Primary outcomes

  1. Photographic Evaluation of Striae Clearance

    Time frame: Follow Up Between 1 and 3 Months Post Last Treatment

    The physician will judge the overall improvement by selecting from improvement ranges of 0-25%, 25-50%, 50-75%, or 75-100% clearance when compared to the baseline.

Sponsors and collaborators

Lead sponsor

Cynosure, Inc.

Industry

Registry information

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Dec 10, 2012
Registry last updated
Feb 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.